Intravitreal Hydrogel-Based Axitinib Implant (OTX-TKI) for the Treatment of Neovascular AMD

A Phase 1 Trial Update

Andrew A. Moshfeghi

University of Southern California Roski Eye Institute

Clinical Trial Investigators: James G. Wong, Andrew A. Chang, Robyn H. Guymer, Sanjeewa S. Wickremasinghe, Alan Luckie, Mark Gillies

Angiogenesis, Exudation and Degeneration Symposium | February 11-12, 2022 | Virtual

Disclosures

Study Disclosures

- Sponsorship for the clinical trial: Ocular Therapeutix, Inc.
- The presentation discusses an investigational product, OTX-TIC. Its efficacy and safety profile has not been established and it has not been approved by the FDA

Presenter Financial Disclosures

- Consulting: Allergan, Genentech, Graybug, Novartis, Ocular Therapeutix, Placid0, Pr3vent, Regeneron, REGENXBIO
- Research Grants: Genentech, Novartis, Regeneron
- Equity Interests: OptiSTENT, Ocular Therapeutix, Placid0, Pr3vent



Based on Phase I trial data currently available*

- OTX-TKI (Axitinib Intravitreal Implant) has been generally well tolerated and observed to have a favorable safety profile, with no ocular serious adverse events to date in all cohorts [Cohort 1(200 µg), Cohort 2(400 µg), Cohort 3a (600 µg) and Cohort 3b (400 µg + Anti-VEGF)]
- Preliminary biological signal of clinically-meaningful decrease in retinal fluid observed by 2 months in Cohorts 2 (400 µg) & 3a (600 µg), and as early as a week in Cohort 3b (400 µg + Anti-VEGF)
- > Over 60% of all subjects showed durability of 6 months or longer including over 80% in Cohort 3a (600 µg)
 - Approximately 50% of all subjects showed durability of 7.5 months or longer

Problems with Immediate-release Injections

Unmet Need in Retinal Disease

- Therapeutic challenges associated with current therapies include
 - Rapid clearance of VEGF inhibitors, requiring repeated injections every 1-2 months to maintain effective concentrations
 - Over time, repeated intravitreal injections can lead to infection, retinal detachment, elevated intraocular pressure and poor patient tolerance¹⁻³
 - Even with flexible regimens (e.g., PRN and T&E protocols), multiple visits and injections challenging for patients/families leading to patient nonadherence and nonpersistence⁴⁻⁵
- To address these challenges, alternate therapies are being investigated that can provide
 - Novel Mechanism of Action
 - Longer Duration of Action

References: 1. Bochot A, Fattal E. Liposomes for intravitreal drug delivery: a state of the art. *J Control Release*. 2012;161(2):628-634. 2. EYLEA Full Prescribing information 2019 <u>https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf</u>. Accessed July 20, 2020. 3. Lucentis Full Prescribing Information 2019 <u>https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125156s111lbl.pdf</u>. Accessed July 20, 2020. 4. Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. *Psychol Health Med*. 2018;23(2):127-140. 5. Okada M, Mitchell P, Finger RP, et al. Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(2):234-247.

Tyrosine Kinase Inhibitors in AMD

Tyrosine Kinase Inhibitors (TKI) Act Directly on VEGF Receptors


- Axitinib is a small molecule multi-receptor tyrosine kinase inhibitor, potent and highly selective inhibitor of VEGFR-1, 2, 3 and PDGFR signaling^{1,2}
- Axitinib acts intracellularly and interferes with cellular signaling through inhibition of the receptor tyrosine kinases²
- Lower doses of axitinib (at nanomolar concentrations) exhibit high potency and selectivity compared to other TKIs (e.g., sunitinib, sorafenib and pazopanib)²

Inhibitory Concentrations (IC50 in nmol) for Multitargeted TKIs²

Drug	VEGFR-1	VEGFR-2	VEGFR-3	PDGFR α	PDGFR β
Axitinib	0.1	0.2	0.1-0.3	5	1.6
Pazopanib	10	30	47	71	84
Sunitinib	10	10	10	5-10	10
Sorafenib		90	20	50-60	50-60

- Lower doses of axitinib may minimize the TKI class-related adverse events resulting from systemic drug concentrations³
- Axitinib has low water solubility⁴ compared to other TKIs (e.g., sunitinib, pazopanib, nintedanib),⁵⁻⁷ allowing for controlled drug release

Tyrosine Kinase Inhibitor Targets



References: 1. Zhao Y, Adjei AA. Oncologist. 2015;20(6):660-673. 2. Gross-Goupil M, François L, Quivy A, Ravaud A. Clin Med Insights Oncol. 2013;7:269-277. (Table adapted from manuscript) 3. Giddabasappa A, Lalwani K, Norberg R, et al.. Experimental Eye Research. 2016;145:373-379. doi:10.1016/j.exer.2016.02.010. 4. PubChem. Axitinib. Accessed October 15, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/6450551. 5. PubChem. Sunitinib. Accessed October 15, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/6450551. 5. PubChem. Sunitinib. Accessed October 15, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/6450551. 5. PubChem. Sunitinib. Accessed October 15, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/6450551. 5. PubChem. Sunitinib. Accessed October 15, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/6450251. 5. PubChem. Nintedanib. Accessed October 15, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/10113978. 7. PubChem. Nintedanib. Accessed October 15, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/135423438

Abbreviations: AMD, age-related macular degeneration; Ang, angiopoietin; FGFR, fibroblast growth factor receptor; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endotheliall growth factor receptor


OTX-TKI (Axitinib Intravitreal Implant) for Intravitreal Injection

Polyethylene glycol (PEG)-based Hydrogel Platform

- Completely biodegrades via ester hydrolysis
- Biocompatible with low potential for inflammation
- Engineered to deliver drug in days or months

Axitinib (Active Ingredient)

- Potential for broader anti-angiogenic profile compared to anti-VEGF agents
- Highly potent compared to other TKIs
- Systemic TKI efficacy established in oncology



OTX-TKI, a novel hydrogel-based, biodegradable, sustained-release axitinib implant

- Goal of delivering axitinib for 6 to 9 months at near zero-order kinetics
- Biodegrades completely and is cleared from the vitreous
- Small fiber with minimal to no visual impact but still allows for physician monitoring
- Free of antimicrobial preservatives

OTX-TKI Phase 1 Study in Australia Study Design

Status

- Cohorts 1, 2, 3a & 3b are fully enrolled
- Cohort 4a and 4b are actively enrolling


Key Inclusion Criteria

- Active primary sub foveal neovascularization secondary to AMD
- Previously treated or naïve subjects
- Presence of retinal fluid

Objectives

- Safety and tolerability
- Biological activity mean change in central subfield thickness measured by SD-OCT, BCVA, and clinically-significant leakage on FA and/or OCT-A

Open-label, Dose Escalation, Feasibility Trial



Question:


Does axitinib (a tyrosine kinase inhibitor; TKI) injected into the eye have biological activity?

Baseline Demographics

	Cohort 1 OTX-TKI 200µg (n=6)	Cohort 2 OTX-TKI 400µg (n=7)	Cohort 3a OTX-TKI 600µg (n=6)	Cohort 3b OTX-TKI 400µg + Anti-VEGF (n=4)	All Subjects (n=23)
Age, years					
Mean (SD)	75.8 (3.7)	74.7 (5.4)	77.3 (5.4)	78.3 (8.1)	76.2 (5.3)
Sex , n (%)					
Male	5 (83.3%)	4 (57.1%)	5 (83.3%)	3 (75.0%)	17 (73.9%)
Female	1 (16.7%)	3 (42.9%)	1 (16.7%)	1 (25.0%)	6 (26.1%)
History of Treatment with anti-VEGF, n (%)					
Previously treated	4 (66.7%)	5 (71.4%)	1 (16.7%)	2 (50.0%)	11 (47.8%)
Treatment naïve	2 (33.3%)	2 (28.6%)	5 (83.3%)	2 (50.0%)	12 (52.2%)
BCVA, ETDRS Letters (Snellen equivalent)					
Mean ± SEM	48 (20/110) ± 12.0	62 (20/63) ± 8.5	46 (20/125) ± 6.4	47 (20/125) ± 11.8	51 (20/100) ± 4.7
CSFT , μm					
Mean ± SEM	680 ± 159	450 ± 29	521 ± 68	435 ± 58	526 ± 49

Durability Assessment

- Anti-VEGF injections leading up to OTX-TKI treatment (estimated)
- Last anti-VEGF injection prior to OTX-TKI treatment (actual)
- Received anti-VEGF injection
- Implant no longer visible
- Continuing follow-up



Each bar represents a single subject (total n=23)

Duration of Effect

Over 60% of all subjects showed durability of 6 months or longer and approximately 50% of subjects showed durability of 7.5 months or longer

	Month 1 % (n/N)	Month 3 % (n/N)	Month 6 % (n/N)	Month 7.5 % (n/N)	Month 9 % (n/N)	Month 12 % (n/N)	Month 14 % (n/N)	Month 17 % (n/N)
Cohort 1 (200 µg)	100% (6/6)	67% (4/6)	50% (3/6)	50% (3/6)	50% (3/6)	NA	NA	NA
Cohort 2 (400 µg)	86% (6/7)	71% (5/7)	57% (4/7)	43% (3/7)	43% (3/7)	29% (2/7)	29% (2/7)	14% (1/5)
Cohort 3a (600 µg)	100% (6/6)	83% (5/6)	83% (5/6)	50% (3/6)	17% (1/6)	20% (1/5)*	50% (1/2)*	100% (1/1)*
Cohort 3b (400 µg + anti- VEGF)	100% (4/4)	100% (4/4)	50% (2/4)	50% (2/4)	33% (1/3)*	0% (0/2)*	0% (0/2)*	TBD
All Cohorts (Pooled)	96% (22/23)	78% (18/23)	61% (14/23)	48% (11/23)	36% (8/22)*	21% (3/14)*	27% (3/11)*	33% (2/6)*


Rescue Criterion:


- If needed, any subject in any treatment arm may receive rescue therapy (i.e., anti-VEGF) at the Investigator's discretion
- The following criteria used to identify subjects who will likely require rescue therapy:
 - i. Loss of ≥ 15 letters from best previous BCVA due to AMD, with current BCVA not better than baseline; or
 - ii. Loss of ≥ 10 letters on 2 consecutive visits from best previous BCVA due to AMD, with current BCVA score not better than baseline
 - iii. Evidence of worsening disease activity manifest by greater than 75 microns CSFT from previous best value

* Follow-up is ongoing


If subjects received rescue anti-VEGF therapy at a study visit, they were counted as rescued at the following study visit in the table above.


SD-OCT Evaluation: Cohort 3






SD-OCT Evaluation: Cohort 2 and 3






Interim Results for All Subjects: Central Subfield Thickness and Visual Acuity Effective control of retinal fluid and vision demonstrating sustained activity over time




Change from Baseline in BCVA

Cohort 1: n=6 until Month 9: Cohort 2: n=7 until Month 12, n=6 for Month 14, n=5 for Month 16 and 17 Cohort 3a: n=6 until Month 11, n=5 for Month 12, n=2 for Month 14, n=1 for Month 16 and 17; Cohort 3b: n=4 until Month 7.5; n=3 for Month 9, n=2 for Month 11 to 14; n=1 for Month 16 All BCVA and CSFT values compared to baseline visit; NOTE: Interim review, unmonitored data; Data cut off January 11, 2022

Interim Results for All Subjects: Central Subfield Thickness and Visual Acuity Evidence of biological activity with axitinib in treatment naive subjects



Previously Treated Subjects (n=12)



---- Treatment Naïve Subjects from Cohorts 1, 2, 3a & 3b (Pooled)

---Previously Treated Subjects from Cohorts 1, 2, 3a & 3b (Pooled)

All BCVA and CSFT values compared to baseline visit. Baseline CSFT and BCVA ± SEM for treatment naïve subjects was 571 ± 88.7 µm and 46 ± 5.6 letters, respectively. Baseline CSFT and BCVA ± SEM for previously treated subjects was 485 ± 47.6 µm and 57 ± 7.4 letters, respectively.

Safety and Tolerability

OTX-TKI has been generally well tolerated and observed to have a favorable safety profile

• No ocular serious adverse events (SAEs) reported

• No reports of significant adverse events such as:

- No endophthalmitis
- No retinal detachment
- No implant migration into the anterior chamber
- No elevated IOP
- No retinal vasculitis

Number of AEs Reported in the Study Eye	Соhort 1 200 µg (1 x 200µg implant) n=6	Cohort 2[†] 400 μg (2 x 200μg implants) n=7	Cohort 3a[†] 600 µg (3 x 200µg implants) n=6	Cohort 3b[†] 400 μg + anti-VEGF (2 x 200μg implants) n=4	Total n=23
Vitreous floaters	0	1	0	1	2
Endophthalmitis	0	0	0	0	0
Retinal detachment	0	0	0	0	0
Implant migration into AC	0	0	0	0	0
Elevated IOP	0	0	0	0	0
Ocular inflammation	0	0	0	1	1
Subconjunctival hemorrhage	1	3	5	3	12
Eye pain	0	2	2	0	4
Pigmented keratic precipitates	3	0	0	0	3

AEs in > 2 subjects

Conclusions to Date

OTX-TKI was generally well tolerated

- To date, observed to have a favorable safety profile, with no ocular serious adverse events in treatment naïve & previously treated wet AMD patients
- No measurable systemic exposure to axitinib observed in Cohort 1, 2, 3a and 3b

Preliminary biological signal of clinically-meaningful decrease in retinal fluid


- Some subjects showed a decrease in intraretinal or subretinal fluid by 2 months in Cohorts 2 (400 μg) & 3a (600 μg)
- Combination of OTX-TKI + Anti-VEGF (Cohort 3b) showed a decrease in intraretinal or subretinal fluid as early as a week after treatment in two subjects

Therapy durability suggests extended duration of action (follow-up ongoing)

- Over 60% of all subjects showed durability of 6 months or longer (including over 80% in the 600 µg group) and approximately 50% of subjects showed durability of 7.5 months or longer
- Consistent bio-resorption observed
 - o Implant biodegraded in Cohort 1 (single implant) by 9-10.5 months
- Implant location observation suggests limited movement
 - o Implant was able to be adequately monitored

OTX-TKI is being evaluated in an ongoing Phase 1b, U.S.-based, prospective, randomized, controlled, multicenter trial

UNMET NEED Longer Duration of Action & Novel Mechanism of Action



OTX-TKI Phase 1b Study in the US

Prospective, multi-center, double-masked, parallel-group study

Status

Actively enrolling

Key Inclusion Criteria

- Active primary sub foveal neovascularization secondary to AMD
- No active fluid

Objectives

- Safety, tolerability, durability and biological activity
- BCVA, mean change in central subfield thickness (CSFT) measured by SD-OCT and safety evaluations at all visits

Key Differences in Study Design:

	US Phase 1b Study	Australia Phase 1 Study
Inclusion Criteria	No active fluid	Presence of retinal fluid
OTX-TKI Implant	One 0.6 mg (600 μg) single implant	Cohorts 1-3 used one to three 0.2 mg (200 µg) implants to achieve different dose levels (0.2, 0.4 and 0.6 mg)
Anti-VEGF Induction	Yes, all subjects	Only in Cohort 3b and 4b

